A23K20/195

METHODS OF MINIMIZING MICROBIAL RESISTANCE IN DOMESTICATED ANIMALS BY INCORPORATING SUSTAINABLE CARBON PRODUCT SUPPLEMENTS INTO ANIMAL FEED
20230043027 · 2023-02-09 ·

The embodiments herein are directed to methods for incorporating high quality, sustainable carbon product into animal feed. In particular, the sustainable carbon product described herein for use in animal feed may be produced as byproducts of efficient, clean energy processes. Utilization of sustainable carbon product produced by such clean energy solutions can provide long-term benefits to the environment, while providing a high-quality feed supplement for treating microbial infections without increasing anti-microbial resistance.

Probiotic Bacterial Molecules and their Use in Methods to Treat/Prevent Infection by Harmful Bacteria and to Provide Nutritional Health

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

Probiotic Bacterial Molecules and their Use in Methods to Treat/Prevent Infection by Harmful Bacteria and to Provide Nutritional Health

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

NOVEL LACTOCOCCUS GARVIEAE BACTERIOPHAGE LAC-GAP-1 AND USE THEREOF IN SUPPRESSING PROLIFERATION OF LACTOCOCCUS GARVIEAE BACTERIA

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

NOVEL LACTOCOCCUS GARVIEAE BACTERIOPHAGE LAC-GAP-1 AND USE THEREOF IN SUPPRESSING PROLIFERATION OF LACTOCOCCUS GARVIEAE BACTERIA

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
20180000793 · 2018-01-04 ·

Provided herein are materials and methods useful for reducing, preventing, and/or inhibiting germination of C. perfringens spores, including methods for inhibiting C. perfringens germination to reduce necrotizing enteritis (NE, also referred to as necrotic enteritis) in animals. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
20180000793 · 2018-01-04 ·

Provided herein are materials and methods useful for reducing, preventing, and/or inhibiting germination of C. perfringens spores, including methods for inhibiting C. perfringens germination to reduce necrotizing enteritis (NE, also referred to as necrotic enteritis) in animals. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

NOVEL LACTOCOCCUS LACTIS SUBSPECIES LACTIS ISOLATE WFLU-12 AND USE THEREOF
20230235276 · 2023-07-27 ·

The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number o KCTC 13180BP, and a use thereof.

NOVEL LACTOCOCCUS LACTIS SUBSPECIES LACTIS ISOLATE WFLU-12 AND USE THEREOF
20230235276 · 2023-07-27 ·

The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number o KCTC 13180BP, and a use thereof.

PROBIOTIC BACTERIAL MOLECULES AND THEIR USE IN METHODS TO TREAT/PREVENT INFECTION BY HARMFUL BACTERIA AND TO PROVIDE NUTRITIONAL HEALTH

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.